2. Academic Validation
  3. Selective peroxisome proliferator-activated receptor δ isosteric selenium agonists as potent anti-atherogenic agents in vivo

Selective peroxisome proliferator-activated receptor δ isosteric selenium agonists as potent anti-atherogenic agents in vivo

  • Bioorg Med Chem Lett. 2010 Dec 15;20(24):7239-42. doi: 10.1016/j.bmcl.2010.10.103.
Jungwook Chin 1,  Jun Young Hong,  Jaehwan Lee,  Hoosang Hwang,  Hyunsil Ko,  Hyukjae Choi,  Dongyup Hahn,  Jaeyoung Ko,  Sang-Jip Nam,  Jungae Tak,  Jungyeob Ham,  Heonjoong Kang
Affiliations

Affiliation

  • 1 Center for Marine Natural Products and Drug Discovery, School of Earth and Environmental Sciences, Seoul National University, Seoul, Republic of Korea.
PMID: 21074432 DOI: 10.1016/j.bmcl.2010.10.103
Abstract

We report the synthesis and in vivo activity of a novel anti-atherogenic agent, isosteric selenium PPARδ-selective ligand. This ligand did not cause significant body or liver weight changes and did not have obvious adverse effects on intestinal polyp formation. Our overall results clearly demonstrate that PPARδ is a viable drug candidate for targeting and treating atherosclerosis.

Figures